1. Home
  2. PRME vs LTBR Comparison

PRME vs LTBR Comparison

Compare PRME & LTBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.06

Market Cap

536.4M

Sector

Health Care

ML Signal

HOLD

Logo Lightbridge Corporation

LTBR

Lightbridge Corporation

HOLD

Current Price

$7.98

Market Cap

575.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRME
LTBR
Founded
2019
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
536.4M
575.6M
IPO Year
2022
2015

Fundamental Metrics

Financial Performance
Metric
PRME
LTBR
Price
$3.06
$7.98
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$7.56
N/A
AVG Volume (30 Days)
2.5M
905.3K
Earning Date
05-08-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
18.18
N/A
EPS
N/A
N/A
Revenue
$4,632,000.00
N/A
Revenue This Year
$7.06
N/A
Revenue Next Year
$47.01
N/A
P/E Ratio
N/A
N/A
Revenue Growth
55.28
N/A
52 Week Low
$2.67
$6.92
52 Week High
$6.94
$31.34

Technical Indicators

Market Signals
Indicator
PRME
LTBR
Relative Strength Index (RSI) 45.78 41.86
Support Level $2.73 $6.92
Resistance Level $3.32 $8.65
Average True Range (ATR) 0.18 0.57
MACD 0.02 -0.03
Stochastic Oscillator 54.62 8.99

Price Performance

Historical Comparison
PRME
LTBR

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About LTBR Lightbridge Corporation

Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.

Share on Social Networks: